Majid Al-Qurahi, Derek Fleming, Won-Jun Kim, Ibrahim Bozyel, Robin Patel, Haluk Beyenal
{"title":"Electrochemical Catheter Hub Operated by a Wearable Micropotentiostat Prevents Acinetobacter baumannii Infection In Vitro","authors":"Majid Al-Qurahi, Derek Fleming, Won-Jun Kim, Ibrahim Bozyel, Robin Patel, Haluk Beyenal","doi":"10.1002/bit.28990","DOIUrl":null,"url":null,"abstract":"<p>Intraluminal infection of central venous catheters, used for long-term treatment, can result in central line-associated bloodstream infection (CLABSI). These infections can be challenging to prevent and treat due to formation of biofilms within catheter lumens, which shield bacteria from the human immune response and conventional antimicrobial therapies. Preventing bacterial colonization of catheter hubs is a strategy to prevent CLABSI. To address this, we developed a nonantibiotic, animal-ready electrochemical catheter hub (e-catheter hub), operated by a wearable, battery-powered micropotentiostat (MP), that internally generates tunable hypochlorous acid (HOCl) for preventing intraluminal infection. The design evaluated three different electrode materials—titanium, platinum, and gold—for HOCl generation and biocidal activity, using working and counter electrodes of the same materials and a silver/silver chloride-plated wire as a quasi-reference electrode. e-catheter hubs operated by MPs at 1.5 V<sub>Ag/AgCl</sub> for 3 h generated HOCl, reducing <i>Acinetobacter baumannii</i> ATCC-17978 below the detection limit (average reduction of 4.40 ± 0.05 log<sub>10</sub> CFU/mL). The efficacy of e-catheter hubs operated by MPs in generating HOCl and achieving biocidal activity is comparable to that of a commercial potentiostat. This study represents the first step in developing a localized, nonantibiotic strategy to mitigate CLABSI risk.</p>","PeriodicalId":9168,"journal":{"name":"Biotechnology and Bioengineering","volume":"122 7","pages":"1828-1839"},"PeriodicalIF":3.6000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bit.28990","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology and Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bit.28990","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Intraluminal infection of central venous catheters, used for long-term treatment, can result in central line-associated bloodstream infection (CLABSI). These infections can be challenging to prevent and treat due to formation of biofilms within catheter lumens, which shield bacteria from the human immune response and conventional antimicrobial therapies. Preventing bacterial colonization of catheter hubs is a strategy to prevent CLABSI. To address this, we developed a nonantibiotic, animal-ready electrochemical catheter hub (e-catheter hub), operated by a wearable, battery-powered micropotentiostat (MP), that internally generates tunable hypochlorous acid (HOCl) for preventing intraluminal infection. The design evaluated three different electrode materials—titanium, platinum, and gold—for HOCl generation and biocidal activity, using working and counter electrodes of the same materials and a silver/silver chloride-plated wire as a quasi-reference electrode. e-catheter hubs operated by MPs at 1.5 VAg/AgCl for 3 h generated HOCl, reducing Acinetobacter baumannii ATCC-17978 below the detection limit (average reduction of 4.40 ± 0.05 log10 CFU/mL). The efficacy of e-catheter hubs operated by MPs in generating HOCl and achieving biocidal activity is comparable to that of a commercial potentiostat. This study represents the first step in developing a localized, nonantibiotic strategy to mitigate CLABSI risk.
期刊介绍:
Biotechnology & Bioengineering publishes Perspectives, Articles, Reviews, Mini-Reviews, and Communications to the Editor that embrace all aspects of biotechnology. These include:
-Enzyme systems and their applications, including enzyme reactors, purification, and applied aspects of protein engineering
-Animal-cell biotechnology, including media development
-Applied aspects of cellular physiology, metabolism, and energetics
-Biocatalysis and applied enzymology, including enzyme reactors, protein engineering, and nanobiotechnology
-Biothermodynamics
-Biofuels, including biomass and renewable resource engineering
-Biomaterials, including delivery systems and materials for tissue engineering
-Bioprocess engineering, including kinetics and modeling of biological systems, transport phenomena in bioreactors, bioreactor design, monitoring, and control
-Biosensors and instrumentation
-Computational and systems biology, including bioinformatics and genomic/proteomic studies
-Environmental biotechnology, including biofilms, algal systems, and bioremediation
-Metabolic and cellular engineering
-Plant-cell biotechnology
-Spectroscopic and other analytical techniques for biotechnological applications
-Synthetic biology
-Tissue engineering, stem-cell bioengineering, regenerative medicine, gene therapy and delivery systems
The editors will consider papers for publication based on novelty, their immediate or future impact on biotechnological processes, and their contribution to the advancement of biochemical engineering science. Submission of papers dealing with routine aspects of bioprocessing, description of established equipment, and routine applications of established methodologies (e.g., control strategies, modeling, experimental methods) is discouraged. Theoretical papers will be judged based on the novelty of the approach and their potential impact, or on their novel capability to predict and elucidate experimental observations.